[go: up one dir, main page]

DK1027053T3 - Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser - Google Patents

Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser

Info

Publication number
DK1027053T3
DK1027053T3 DK98952186T DK98952186T DK1027053T3 DK 1027053 T3 DK1027053 T3 DK 1027053T3 DK 98952186 T DK98952186 T DK 98952186T DK 98952186 T DK98952186 T DK 98952186T DK 1027053 T3 DK1027053 T3 DK 1027053T3
Authority
DK
Denmark
Prior art keywords
administration
patient
cyclosporin
tacrolimus
pps
Prior art date
Application number
DK98952186T
Other languages
English (en)
Inventor
Gary E Striker
Lilliane Striker
Kenneth H Kortright
Original Assignee
Ivax Research Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Research Inc, Us Health filed Critical Ivax Research Inc
Application granted granted Critical
Publication of DK1027053T3 publication Critical patent/DK1027053T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
DK98952186T 1997-10-09 1998-10-09 Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser DK1027053T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6294797P 1997-10-09 1997-10-09

Publications (1)

Publication Number Publication Date
DK1027053T3 true DK1027053T3 (da) 2004-09-06

Family

ID=22045901

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98952186T DK1027053T3 (da) 1997-10-09 1998-10-09 Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser

Country Status (23)

Country Link
US (1) US6187745B1 (da)
EP (1) EP1027053B1 (da)
JP (1) JP2001519392A (da)
KR (1) KR100515196B1 (da)
CN (1) CN1154492C (da)
AT (1) ATE269098T1 (da)
AU (1) AU748495B2 (da)
BR (1) BR9813860A (da)
CA (1) CA2304374A1 (da)
CZ (1) CZ297440B6 (da)
DE (1) DE69824619T2 (da)
DK (1) DK1027053T3 (da)
ES (1) ES2221714T3 (da)
HU (1) HUP0003904A3 (da)
IL (1) IL135235A0 (da)
NO (1) NO20001828L (da)
NZ (1) NZ503493A (da)
PL (1) PL191993B1 (da)
PT (1) PT1027053E (da)
RU (1) RU2191020C2 (da)
SK (1) SK285332B6 (da)
UA (1) UA65587C2 (da)
WO (1) WO1999018961A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052867A1 (en) * 2000-01-19 2001-07-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of pentosan polysulfate to treat certain conditions of the prostate
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7060672B2 (en) * 2001-10-19 2006-06-13 Isotechnika, Inc. Cyclosporin analog formulations
IL164185A0 (en) * 2002-04-16 2005-12-18 Fujisawa Pharmaceutical Co Pharmaceutical compositions containing trifluoromethylphenyl amide derivatives
EP1748781B1 (en) 2004-05-27 2012-12-19 Baxter International Inc. Methods for treating bleeding disorders using sulfated polysaccharides
JP5896742B2 (ja) 2008-08-22 2016-03-30 バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA 出血性障害を処置するための方法
US8632991B2 (en) 2010-01-14 2014-01-21 Baxter International Inc. Methods and compositions for treating bleeding disorders
WO2011088418A2 (en) * 2010-01-15 2011-07-21 Mount Sinai School Of Medicine Inhibition of tnf-alpha induced activation of nfkb by pentosan polysulfate
CN102327282A (zh) * 2010-09-01 2012-01-25 吴洪 戊糖多聚硫酸酯用于制备治疗糖尿病肾病的药物中的用途
CA2838793C (en) 2011-07-19 2019-08-06 Baxter International Inc. Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
RU2014117580A (ru) * 2011-10-05 2015-11-10 Аллерган, Инк. Составы для улучшения здоровья ногтей
US9417251B2 (en) 2012-08-14 2016-08-16 Baxalta GmbH Methods and systems for screening compositions comprising non-anticoagulant sulfated polysaccharides
KR101760510B1 (ko) 2014-12-18 2017-07-21 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
WO2016099214A1 (ko) * 2014-12-18 2016-06-23 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
KR20180011840A (ko) * 2015-06-12 2018-02-02 비샬 자조디아 스와티 방광 출구 폐쇄 및/또는 하부 요로 증상의 치료에서 사용하기 위한 펜토산폴리설페이트나트륨을 포함하는 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843241A1 (de) * 1988-12-22 1990-06-28 Skrezek Christian Nephroprotektive infusionsloesung
EP0466315A3 (en) 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
GB9116836D0 (en) * 1991-08-05 1991-09-18 Sandoz Ltd Organic compounds
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
RU2027471C1 (ru) * 1992-04-14 1995-01-27 Северо-Кавказский горно-металлургический институт Способ очистки суспензий и вибрационный фильтр-сгуститель для его осуществления
IT1277147B1 (it) * 1995-01-20 1997-11-04 Sigma Tau Ind Farmaceuti Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.
JPH08208489A (ja) * 1995-02-03 1996-08-13 L T T Kenkyusho:Kk 腎不全治療剤
US5643892A (en) * 1995-06-07 1997-07-01 Baker Norton Pharmaceuticals, Inc. Method of treating chronic progressive vascular diseases

Also Published As

Publication number Publication date
ES2221714T3 (es) 2005-01-01
EP1027053B1 (en) 2004-06-16
PL339774A1 (en) 2001-01-02
AU748495B2 (en) 2002-06-06
HUP0003904A3 (en) 2006-06-28
SK285332B6 (sk) 2006-11-03
RU2191020C2 (ru) 2002-10-20
NO20001828L (no) 2000-05-15
CA2304374A1 (en) 1999-04-22
WO1999018961A1 (en) 1999-04-22
EP1027053A1 (en) 2000-08-16
PT1027053E (pt) 2004-09-30
DE69824619T2 (de) 2005-06-23
SK4672000A3 (en) 2001-09-11
BR9813860A (pt) 2001-03-20
KR20010030749A (ko) 2001-04-16
EP1027053A4 (en) 2002-05-22
ATE269098T1 (de) 2004-07-15
PL191993B1 (pl) 2006-08-31
CN1275080A (zh) 2000-11-29
CZ20001274A3 (cs) 2001-12-12
HK1026845A1 (en) 2000-12-29
NZ503493A (en) 2001-11-30
CZ297440B6 (cs) 2006-12-13
DE69824619D1 (de) 2004-07-22
JP2001519392A (ja) 2001-10-23
UA65587C2 (en) 2004-04-15
IL135235A0 (en) 2001-05-20
HUP0003904A1 (hu) 2001-08-28
NO20001828D0 (no) 2000-04-07
US6187745B1 (en) 2001-02-13
KR100515196B1 (ko) 2005-09-16
AU9794398A (en) 1999-05-03
CN1154492C (zh) 2004-06-23

Similar Documents

Publication Publication Date Title
DK1027053T3 (da) Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
CO5261582A1 (es) Composiciones de valdecoxib
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
JP2002523370A5 (da)
KR910019618A (ko) 발기부전증 치료용 제약 조성물
CA2277365A1 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
KR19980701720A (ko) 세스키테르펜 락톤 및 비타민 b 복합체를 함유하는 편두통 및 기타 질환 치료용 복합약
MY124465A (en) Reduction of infarct volume using citicoline
CA2537748A1 (en) Use of telmisartan for the prevention of vascular headache
KR900011461A (ko) 트립스타틴을 유효성분으로 하는 치료제
EP0190851B1 (en) Improved antiinflammatory composition
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
KR890004705A (ko) 항바이러스성 제제
BE1002255A5 (fr) Medicaments.
NL8105635A (nl) Geneesmiddel met transplantaatafstotings- en/of immunologische ontstekingsremmende werking, alsmede werkwijze voor de remming van transplantaatafstoting en/of immunologische ontsteking.
BE1002256A3 (fr) Medicaments.
RU99112967A (ru) Способ лечения и профилактики дизентерии свиней
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
NZ315632A (en) Process for preparing solid dosage forms of very low-dose drugs comprising admixing 1-3% by weight of carrier particles with a solution of drug in water
KR830008678A (ko) 진통 조성물